<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175759</url>
  </required_header>
  <id_info>
    <org_study_id>34/2009</org_study_id>
    <nct_id>NCT01175759</nct_id>
  </id_info>
  <brief_title>Role of Hypersensitivity to Female Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of the EVE- Skin-Test Panel in Detecting Sensitivity to Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EVE Medical Systems Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EVE Medical Systems Ltd.</source>
  <brief_summary>
    <textblock>
      The EVE- technology is intended for determination of intolerance or sensitivity to female sex&#xD;
      hormones among women with hormone-related conditions and for further treatment by&#xD;
      desensitization procedure inducing a tolerance to the hormones the women are sensitive to.&#xD;
&#xD;
      This study is designed to evaluate the safety and the ability of the EVE- Skin-Test Panel to&#xD;
      detect sensitivity to female sex hormones in subjects with Unexplained Recurrent Pregnancy&#xD;
      Loss (URPL) and in Control parous, healthy women.&#xD;
&#xD;
      The Skin Test Panel includes four female hormones and three control solutions.&#xD;
&#xD;
      Hormones from the Skin Test Panel are injected intradermally during the luteal phase of the&#xD;
      subject's menstrual cycle. The skin reactions are examined by physician for erythema and&#xD;
      wheal after 20 minutes and 48 hours and self-assessed by the patient daily for the following&#xD;
      month.&#xD;
&#xD;
      Skin response monthly data is analyzed and compared between unexplained recurrent pregnancy&#xD;
      loss (UPRL) and healthy groups.&#xD;
&#xD;
      Following achievement of the significant differences between both groups the immune profile&#xD;
      of the healthy and UPRL subjects will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with positive wheal responses to the Skin Test Panel in URPL and Control groups</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events following a skin test procedure in subjects from URPL and Control groups</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of cytokine production in subjects from UPRL and Control groups</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Abortion, Recurrent</condition>
  <arm_group>
    <arm_group_label>Healthy control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>UPRL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Skin test panel</intervention_name>
    <description>Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.&#xD;
Hormones:&#xD;
Progesterone 1mmol/L&#xD;
Estradiol 1mmol/L&#xD;
Estrone 3mmol/L&#xD;
Estriol 3mmol/l&#xD;
Controls:&#xD;
Saline (NaCl) 0.9%&#xD;
Ethyl Oleate with 10% Benzyl Alcohol&#xD;
Histamine phosphate 1mg/ml (epicutaneous- prick test)</description>
    <arm_group_label>Healthy control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Skin test panel</intervention_name>
    <description>Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.&#xD;
Hormones:&#xD;
Progesterone 1mmol/L&#xD;
Estradiol 1mmol/L&#xD;
Estrone 3mmol/L&#xD;
Estriol 3mmol/l&#xD;
Controls:&#xD;
Saline (NaCl) 0.9%&#xD;
Ethyl Oleate with 10% Benzyl Alcohol&#xD;
Histamine phosphate 1mg/ml (epicutaneous- prick test)</description>
    <arm_group_label>UPRL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For both groups:&#xD;
&#xD;
          1. Between ages of 20 to 40&#xD;
&#xD;
          2. Willing to participate as shown by signing the informed consent form.&#xD;
&#xD;
        For healthy group:&#xD;
&#xD;
        Parous subjects without premenstrual syndrome, as per medical history and subject's report&#xD;
        ( PMS questionnaire)&#xD;
&#xD;
        For UPRL:&#xD;
&#xD;
        Women with three or more documented early pregnancy losses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For both groups:&#xD;
&#xD;
          1. No hormonal contraceptives (either OC or hormonal IUD (Mirena)), no psychotropic&#xD;
             agents (e.g. Antidepressants, anxiolytics, or lithium carbonate) for at least two&#xD;
             months prior to screening.&#xD;
&#xD;
          2. No hormonal therapy (estrogen or progesterone) for at least two months prior to&#xD;
             screening.&#xD;
&#xD;
          3. Significant medical or psychiatric disease.&#xD;
&#xD;
          4. Severe allergies or an inflammatory illness at the time of enrollment&#xD;
&#xD;
        For healthy group:&#xD;
&#xD;
          1. Women who are pregnant or lactating on the day of screening&#xD;
&#xD;
          2. Abnormal routine blood tests&#xD;
&#xD;
        For UPRL:&#xD;
&#xD;
          1. Hereditary thrombophilias (Factor V Leiden, Activated protein C resistance, MTHFR&#xD;
             (C677T), Factor II mutation (G20201A))&#xD;
&#xD;
          2. One or more abnormal test from the list below:&#xD;
&#xD;
               1. Karyotype of either parent (normal: 46XX or 46XY)&#xD;
&#xD;
               2. Glucose tolerance test (This can be altered to fasting blood sugar of 100mg/dl or&#xD;
                  less);&#xD;
&#xD;
               3. Toxoplasmosis serology (IgM positive);&#xD;
&#xD;
               4. Hysterosalpingogram, 3-D ultrasound or hysteroscopy, thereby excluding anatomical&#xD;
                  abnormalities, intrauterine adhesions and cervical incompetence;&#xD;
&#xD;
               5. Thyroid function (Euthyroid levels;);&#xD;
&#xD;
               6. Serum prolactin;&#xD;
&#xD;
               7. Normal luteal phase of at least 12 days and plasma progesterone above 24 ng/lL&#xD;
&#xD;
               8. Anti nuclear factor (Negative)&#xD;
&#xD;
               9. Anticardiolipin antibody by Elisa testing (cut off value &lt;13 GPLu/mL and &lt;7.6&#xD;
                  MPLu/mlL) and Lupus anticoagulant (according to Kaolin clotting time (KCT),&#xD;
                  Russell's viper venom tome (RVVT) or APTT.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>János Rigó, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecology and Obstetrics Dept, Semmelweis University, Budapest, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henriette Farkas, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>3rd Dept of Internal Medicine, Semmelweis University, Budapest, Hungary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Füst, Prof.</last_name>
    <phone>361-212-9351</phone>
    <email>fustge@kut.sote.hu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Depts. Gynecology and Obstetrics and 3rd Dept of Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>H1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Füst, Prof.</last_name>
      <phone>361-212-9351</phone>
      <email>fustge@kut.sote.hu</email>
    </contact>
    <investigator>
      <last_name>János Rigó, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henriette Farkas, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <last_update_submitted>August 4, 2010</last_update_submitted>
  <last_update_submitted_qc>August 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Yonit Bomstein</name_title>
    <organization>EVE Medical systems Ltd.</organization>
  </responsible_party>
  <keyword>Unexplained Recurrent Pregnancy Loss</keyword>
  <keyword>Recurrent Abortions</keyword>
  <keyword>Recurrent Miscarriages</keyword>
  <keyword>Hormones</keyword>
  <keyword>Skin tests</keyword>
  <keyword>Allergen</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Skin reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Habitual</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

